Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 356

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 356
---
 REDEEMABLE COMMON STOCK, AND STOCKHOLDERS’ DEFICIT                                                                                 |     | $            |   8,560,610 |   |     | $    |  42,367,032 |   |

<div align='center'>The accompanying notes are an integral part of the financial statements.

F-27

PHOENIX BIOTECH ACQUISITION CORP.

STATEMENTS OF OPERATIONS</div>

|                                                |     | For                     
 the Year Ended December 
 31,                     |       2023 |   |     |   |       2022 |   |
|:-----------------------------------------------|:----|:------------------------|-----------:|:--|:----|:--|-----------:|:--|
| OPERATING EXPENSES                             |     |                         |            |   |     |   |            |   |
| General and administrative                     |     | $                       |  2,892,935 |   |     | $ |  2,841,391 |   |
| Franchise tax                                  |     |                         |     40,050 |   |     |   |     64,050 |   |
| Loss from operations                           |     |                         | (2,932,985 | ) |     |   | (2,905,441 | ) |
| Other income:                                  |     |                         |            |   |     |   |            |   |
| Interest income earned on marketable           
 securities held in Trust Account               |     |                         |    491,571 |   |     |   |  2,836,864 |   |
| Total other income                             |     |                         |    491,571 |   |     |   |  2,836,864 |   |
| Loss before provision for income taxes         |     |                         | (2,441,414 | ) |     |   |    (68,577 | ) |
| Provision for income taxes                     |     |                         |    (94,819 | ) |     |   |   (599,159 | ) |
| Net loss                                       |     | $                       | (2,536,233 | ) |     | $ |   (667,736 | ) |
| Weighted average shares outstanding of Class A 
 common stock                                   |     |                         |  4,224,247 |   |     |   | 17,896,428 |   |
| Basic and